In a pregnant woman with a thyroid‑stimulating hormone (TSH) level of 7.5 mIU/L and no prior thyroid disease, how should this be managed?

Management of TSH 7.5 mIU/L in Pregnancy

Initiate levothyroxine immediately to normalize TSH into the trimester-specific reference range, targeting TSH <2.5 mIU/L in the first trimester, because untreated maternal hypothyroidism significantly increases risks of preeclampsia, low birth weight, and permanent neurodevelopmental deficits in the offspring. 1

Immediate Treatment Protocol

Starting Dose Selection

• For new-onset hypothyroidism with TSH ≥7.5 mIU/L in pregnancy, start levothyroxine at 1.0–1.6 mcg/kg/day based on the severity of TSH elevation; a TSH of 7.5 mIU/L falls between the <10 and ≥10 thresholds, so 1.0 mcg/kg/day is appropriate. 1, 2
• Calculate the dose using pre-pregnancy or current body weight—for example, a 70 kg woman would receive approximately 70 mcg daily as the starting dose. 2

Critical Timing Considerations

• Treatment must begin immediately upon diagnosis because fetal brain development depends critically on maternal thyroid hormone, particularly during the first and second trimesters when the fetal thyroid is not yet functional. 1
• Delaying treatment even by weeks can result in irreversible neurodevelopmental harm to the fetus. 1

Monitoring Schedule

Initial Phase (Until Stable)

• Measure TSH and free T4 every 4 weeks after starting levothyroxine until TSH reaches the trimester-specific reference range (ideally <2.5 mIU/L in the first trimester). 1, 2
• Adjust the levothyroxine dose by 12.5–25 mcg increments based on TSH results at each 4-week interval. 1

Maintenance Phase

• Once TSH is stable within the target range, continue monitoring TSH at minimum once per trimester throughout the remainder of pregnancy. 1, 2
• Levothyroxine requirements typically increase by 25–50% during pregnancy in women with pre-existing hypothyroidism, so dose adjustments are common and expected. 1

Target TSH Ranges by Trimester

• First trimester: TSH <2.5 mIU/L 1
• Second and third trimesters: maintain TSH within trimester-specific reference ranges (typically 0.5–3.0 mIU/L, though laboratory-specific ranges should be used). 1
• The goal is to maintain serum TSH in the trimester-specific reference range throughout pregnancy. 2

Risks of Inadequate Treatment

Maternal Complications

• Untreated or inadequately treated maternal hypothyroidism increases the risk of preeclampsia, a potentially life-threatening hypertensive disorder of pregnancy. 1
• Maternal hypothyroidism is associated with increased risk of gestational hypertension and placental abruption. 1

Fetal and Neonatal Complications

• Inadequate treatment is associated with low birth weight in neonates, reflecting impaired fetal growth. 1
• Maternal hypothyroidism from iodine deficiency (or inadequate treatment) increases the risk of congenital cretinism, characterized by growth failure, mental retardation, and permanent neuropsychological defects. 1
• Even subclinical maternal hypothyroidism (TSH >2.5 mIU/L with normal free T4) may be associated with adverse pregnancy outcomes and potential neurodevelopmental effects in offspring. 3, 1

Post-Delivery Management

Immediate Postpartum

• Reduce levothyroxine dose to pre-pregnancy levels immediately after delivery, as the increased requirements of pregnancy resolve rapidly. 2
• Monitor serum TSH 4–8 weeks postpartum to confirm appropriate dosing. 2

Neonatal Considerations

• Inform the newborn's physician about maternal hypothyroidism due to the risk of transient neonatal thyroid dysfunction, though this is rare with adequately treated maternal hypothyroidism. 1

Common Pitfalls to Avoid

Delayed Treatment Initiation

• Do not wait for repeat testing or "watchful waiting" when TSH is 7.5 mIU/L in pregnancy—this level clearly exceeds the pregnancy-specific threshold of 2.5 mIU/L and requires immediate treatment. 1
• The 30–60% spontaneous normalization rate seen in non-pregnant adults does not apply to pregnancy, where even mild TSH elevations carry fetal risk. 3

Inadequate Dose Titration

• Do not target the non-pregnant TSH reference range (0.5–4.5 mIU/L)—pregnancy requires stricter TSH control with trimester-specific targets. 1, 2
• Failure to increase the levothyroxine dose adequately during pregnancy (when requirements rise by 25–50%) results in undertreated hypothyroidism and fetal harm. 1

Monitoring Frequency Errors

• Do not monitor TSH less frequently than every 4 weeks during dose titration or less than once per trimester once stable—pregnancy is a dynamic state requiring close surveillance. 1, 2

Evidence Quality Considerations

• The recommendation to treat TSH >2.5 mIU/L in pregnancy is based on fair-quality evidence from observational studies and expert consensus, recognizing that randomized trials of untreated maternal hypothyroidism would be unethical. 3, 1
• The association between maternal hypothyroidism and adverse pregnancy outcomes (preeclampsia, low birth weight, neurodevelopmental effects) is consistently demonstrated across multiple studies. 1
• Levothyroxine requirements increase during pregnancy in approximately 85% of women with pre-existing hypothyroidism, necessitating proactive dose adjustments. 1, 2